TORONTO, Dec. 11, 2013 /CNW/ - MaRS Innovation, a Centre of Excellence for Commercialization and Research, has
announced the first project funded through the Pfizer Inc. and MaRS
Innovation strategic partnership.
Dr. Stuart Berger, senior scientist at University Health Network, has developed a potential innovation for the bio-manufacturing sector,
which is a rapid-growth area. His technology generates cell lines with
improved protein production and survival properties, important in the
industrial production of therapeutic proteins.
Read this release in French.
Current estimates place the global market for therapeutic proteins at
over $100 billion dollars, which is expected to grow at 12 per cent
annually.1 In addition to therapeutic proteins, Dr. Berger's modular technology
can potentially be used in other sectors such as reagent manufacturing
for clinical diagnostics and laboratory research. The technology was
previously funded through MaRS Innovation's Proof-of-Principal
early-stage research funding program, managed on behalf of the
Government of Ontario.
"Dr. Berger's technology addresses a real market need in
bio-manufacturing in that it decreases the high costs associated with
protein production," said Dr. Raphael Hofstein, president and CEO of MaRS Innovation. "This is an excellent example of
an innovation emerging from Canadian investment in basic scientific
"MaRS Innovation's support was critical in getting this technology
developed," added Dr. Berger. "We are delighted that we are now working
with Pfizer with the goal of further advancing our technology."
MaRS Innovation and Pfizer are jointly funding work in Dr. Berger's lab
that will be conducted independently and seeks to further validate the
technology. Both parties will also continue to review additional
opportunities emerging from well-validated scientific research
discoveries within MaRS Innovation's 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals.
"Pfizer is pleased to partner on this initiative with MaRS Innovation
that brings together the scientific community and industry for the
pursuit of knowledge," said Bernard Prigent, Vice-President and Medical
Director, Pfizer Canada Inc. "This research initiative exemplifies the
type of partnership collaborations that Pfizer is seeking with its new
About MaRS Innovation
MaRS Innovation (MI) is the commercialization agent for Ontario's
exceptional discovery pipeline from 16 leading academic institutions. As a single-entry point to $1 billion in annual research and
development, MI is a gateway for investors and licensees to access
technology assets. Supported by the Government of Canada through the Networks of Centres of Excellence, by the Government of Ontario through the Ontario Centres of Excellence, and by its 16 member institutions, MI is a transformational
partnership that turns research strengths into commercial
opportunities. Its portfolio includes the most promising assets from
its members' pipeline, which it advances into global markets through
industry partnerships, licensing and company creation. For more
information, see http://www.marsinnovation.com.
1 According to BCC Market Research Forecasting's 2011 "Biologic
Therapeutic Drugs: Technologies and Global Markets" report, markets for
monoclonal ab and therapeutic proteins added up to $109 billion in 2009
and are growing at a compound annual growth rate of between 8.4 to 12.4
Image with caption: "Dr. Stuart Berger, senior scientist at University Health Network, has developed a potential innovation for the bio-manufacturing sector, which is a rapid-growth area. His technology is being commercialized by MaRS Innovation. (CNW Group/MaRS Innovation)". Image available at: http://photos.newswire.ca/images/download/20131211_C9664_PHOTO_EN_34851.jpg
SOURCE: MaRS Innovation
For further information:
Marketing and Communications Manager